Rheumatology Unit, S. Giovanni di Dio Hospital, Azienda USL-Toscana Centro, Florence, Italy.
Immunology and Allergology Laboratory, S. Giovanni di Dio Hospital, Azienda USL-Toscana Centro, Florence, Italy.
Clin Exp Rheumatol. 2021 Jan-Feb;39(1):196-202. doi: 10.55563/clinexprheumatol/7afn90. Epub 2021 Feb 5.
Since January 2020, the whole world has been facing the worst epidemic for a century. SARS-CoV- 2 infection has so far caused more than one million deaths, with the only measures capable of containing the spread of the virus being social distancing, frequent hand washing, and the wearing of masks. Vaccine development was urgently needed and there are now more than 90 candidate vaccines being developed using different technologies. The European Medicines Agency has recently approved a second mRNA-based vaccine, but the introduction of vaccines has raised some doubts about patients with rheumatic disease, who are at high risk of infection because of disease activity and the therapies used to treat it. The aim of this study was to investigate how vaccines may interact with the immune system and treatment of such patients, and how to monitor the post-vaccine antibody titres and T cell responses in order to assess their efficacy and safety.
自 2020 年 1 月以来，全世界一直在应对一个世纪以来最严重的疫情。SARS-CoV-2 感染迄今已造成 100 多万人死亡，唯一能够控制病毒传播的措施是保持社交距离、勤洗手和戴口罩。急需开发疫苗，目前正在使用不同技术开发 90 多种候选疫苗。欧洲药品管理局最近批准了第二种基于 mRNA 的疫苗，但疫苗的推出引发了人们对风湿性疾病患者的一些质疑，由于疾病活动和用于治疗疾病的疗法，这些患者感染的风险很高。本研究旨在调查疫苗如何与免疫系统相互作用以及如何监测此类患者的疫苗后抗体滴度和 T 细胞反应，以评估其疗效和安全性。
